scholarly journals Pathologocal Complete Response following Pre-operative Chemoradiotherapy for Advanced Rectal Cancer with Abscess Formation—A Case Report—

2016 ◽  
Vol 77 (5) ◽  
pp. 1197-1201
Author(s):  
Yuzo MIYAHARA ◽  
Homare ITO ◽  
Koji KOINUMA ◽  
Yasuyuki MIYAKURA ◽  
Hisanaga HORIE ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Case Report ◽  
Complete Response ◽  
Advanced Rectal Cancer ◽  
Abscess Formation

A case of an enlarged rectal adenoma while achieving a clinical complete response with chemotherapy for advanced rectal cancer

2020 ◽  
Vol 13 (5) ◽  
pp. 782-787 ◽  
Author(s):  
Yasuyuki Nakamura ◽  
Fumikazu Koyama ◽  
Kohei Morita ◽  
Hiroyuki Kuge ◽  
Chiho Ohbayashi ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Complete Response ◽  
Advanced Rectal Cancer ◽  
Rectal Adenoma ◽  
Clinical Complete Response

Diagnosis of Clinical Complete Response by Probe-Based Confocal Laser Endomicroscopy (pCLE) After Chemoradiation for Advanced Rectal Cancer

2021 ◽  
Vol 25 (2) ◽  
pp. 357-368
Author(s):  
Adriana Vaz Safatle-Ribeiro ◽  
Carlos Frederico Sparapan Marques ◽  
Clelma Pires ◽  
Lívia Arraes ◽  
Elisa Ryoka Baba ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Complete Response ◽  
Advanced Rectal Cancer ◽  
Confocal Laser Endomicroscopy ◽  
Confocal Laser ◽  
Clinical Complete Response

scholarly journals Mutational and Clinical Predictors of Pathologic Complete Response in the Treatment of Locally Advanced Rectal Cancer

2013 ◽  
Vol 45 (1) ◽  
pp. 34-39 ◽  
Author(s):  
Andrea L. Russo ◽  
David P. Ryan ◽  
Darrell R. Borger ◽  
Jennifer Y. Wo ◽  
Jackie Szymonifka ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Locally Advanced ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Clinical Predictors

A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer.

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. TPS144-TPS144
Author(s):  
Paul Bernard Romesser ◽  
Emma B. Holliday ◽  
Tony Philip ◽  
Rocio Garcia-Carbonero ◽  
Jaume Capdevila ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Colon Cancer ◽  
Phase Ii ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Rectal Adenocarcinoma ◽  
Complete Response ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Phase Ib

TPS144 Background: Perioperative radiotherapy and chemotherapy, followed by total mesorectal excision, is the standard of care for patients with locally advanced rectal cancer (LARC). However, 1/3 of these patients still develop distant metastases, indicating the need for more effective therapies. In addition, strategies that increase pathological complete response rates are needed to enable non-surgical management of LARC. DNA-dependent protein kinase (DNA-PK) regulates a key DNA damage repair pathway for double-strand break repair. Peposertib (M3814), a potent, selective, orally administered DNA-PK inhibitor, has been shown to potentiate the effect of ionizing radiation in a human colon cancer xenograft model and several colon cancer cell lines. Peposertib is being investigated in several different trials across multiple indications. This Phase Ib/II study (NCT03770689) aims to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of the neoadjuvant treatment combination of peposertib, capecitabine, and radiotherapy (RT) in patients with LARC. Methods: Patients aged ≥18 years with histologically confirmed and resectable Stage II/III rectal adenocarcinoma are eligible. Induction chemotherapy is permitted, but residual disease must first be documented by MRI, digital rectal examination and endoscopy. Patients who received other anticancer therapies or those with prior pelvic RT are excluded. At open-label Phase Ib (open), 18–30 patients (n = 3 per cohort) will receive peposertib + capecitabine (orally, 825 mg/m2 twice daily [BID]) + RT (45–50.4 Gy), 5 days/week. Peposertib 50 mg once daily (QD) was the starting dose. Additional dose levels will range between 100─800 mg QD. Dose escalation is determined by the safety monitoring committee and guided by a Bayesian 2-parameter logistic regression model. At Phase II (planned), 150 patients will be randomized (1:1) to receive oral capecitabine (825 mg/m2 BID) + RT (45–50 Gy), with either oral peposertib (recommended phase II dose [RP2D] or placebo, QD for 5 days/week. Primary objectives are to define a maximum tolerated dose and RP2D (Phase Ib), and to evaluate the efficacy of peposertib + capecitabine + RT in terms of pathological/clinical complete response (Phase II). Secondary objectives include assessment of antitumor activity (Phase Ib), quality of life outcomes (Phase II), and PK of peposertib, and the safety and tolerability of the combination therapy (both phases). To date, one patient has received peposertib 50 mg QD, six patients peposertib 100 mg QD, three patients peposertib 150 mg QD, and three patients peposertib 250 mg QD. Clinical trial information: NCT03770689.

scholarly journals A Case Report: Cutaneous Metastasis of Advanced Rectal Cancer with BRAF Mutation

2021 ◽  
Vol Volume 14 ◽  
pp. 989-993
Author(s):  
Shishi Zhou ◽  
Wanfen Tang ◽  
Qinghua Wang ◽  
Xia Zhang ◽  
Xiayun Jin ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Case Report ◽  
Braf Mutation ◽  
Advanced Rectal Cancer ◽  
Cutaneous Metastasis
Sign in / Sign up

Export Citation Format

Share Document